, and Atrn mg-6J . These are coisogenic on mouse strains LDJ/Le, C3H/HeJ, C3HeB/FeJ, and CAST/Ei, respectively (11, 20) . ATRN is ubiquitously expressed, and it was first identified as a glycoprotein secreted from activated T cells that mediate cell migration and clustering of monocytes. ATRN encodes both secreted and membrane-bound isoforms by alternative splicing (16, 28) . Disruption of the membrane-specific isotype, but not the secreted isotype, of ATRN results in darkened coat color and spongiform neurodegeneration of the Zitter rat (16) . ATRN contains two epidermal growth factor (EGF) domains, two laminin-like EGF repeats, a CUB domain, two plexin-like repeats, a C-type lectin, and seven consecutive Kelch repeats (11, 20) . The functional domains of the ATRN membrane isoform are localized extracellularly, leading to the suggestion by some (11, 20) (11, 20) . MGRN1 is an E3 ubiquitin ligase widely expressed in brain, liver, heart, and kidneys (13, 21) . Mgrn1 md results in partial loss of function, leading to reduced levels of both normal-sized and aberrant transcripts.
Mg and md are negative modifiers of adiposity and yellow coat pigmentation in A y mice (18) . Whereas Atrn mg completely suppresses A y -induced obesity on a uniform C57BL/6J background (18), the effect is much less striking in diet-induced obesity (DIO) in C3Heb/FeJ mice (8, 20) . Atrn mg has no effect on the obesity of mice null for Mc4r, Lepr, Lep, tub, or Cpe (8, 20) . In nonalbino mice, Mgrn1 md darkens hairs on the dorsum, ears, and tail in a dose-dependent manner (18) and suppresses A y -induced yellow pigmentation and obesity (18) . Homozygous Mgrn1 md non-A y mice are hyperphagic but lean on a C3H/HeJ background (8) , suggesting that Mgrn1 md may reduce body fat by increasing energy expenditure and that Mgrn1 md has effects on energy homeostasis distinct from epistatic effects on overexpression of agouti signaling protein (ASP). Genetic studies position MGRN1 and ATRN functionally at the same level or upstream of melanocortin-1 receptor (MC1R) and melanocortin-3 receptor (MC3R)/melanocortin-3 receptor (MC4R), and downstream of ASP, on the basis of the ability of Mgrn1 md and Atrn mg to suppress the effects of A y on coat color and obesity (18) and their inability to suppress the yellow coat of a null mutation (extension) of MC1R (Mc1r e ) (18, 22) . The parallel molecular pathways of peripheral ASP/MC1R and central agouti-related protein (AgRP)/MC3R/MC4R suggest that wild-type MGRN1 acts through analogous mechanisms in the skin and hypothalamus, decreasing signaling through cutaneous MC1R to increase pheomelanin (yellow pigment) synthesis, and through hypothalamic MC3R/MC4R to increase food intake, decrease energy expenditure, and decrease insulin sensitivity (Fig. 1) . In this study, we assessed whether the effects of Mgrn1 md on adiposity and insulin homeostasis were specific to circumstances of overexpression of ASP in the A y mouse or were generalizable to other genetic or dietary causes of obesity such as leptin deficiency (Lep ob ) or DIO. 
MATERIALS AND METHODS

Animal
Measurement of Plasma Glucose, Insulin, and Leptin
At the time of death by CO2 asphyxiation, ϳ0.5-1 ml of whole blood was withdrawn by cardiac puncture and transferred to a tube containing 50 l anticoagulant (82 M EDTA and 10,000 U/ml heparin) and protease inhibitor (1,000 U/ml aprotinin). Samples were centrifuged at 14,000 rpm for 15 min, and plasma was decanted. Plasma glucose was measured by using an enzymatic (glucose oxidase, trinder reagent) assay (Sigma Diagnostic, St. Louis, MO). Plasma insulin was quantified using 1-2-3 Ultra-Sensitive Mouse Insulin ELISA (Alpco Diagnostics, Windham, NH). Plasma leptin was measured with an AC-TIVE Murine Leptin Enzyme-Linked Immunosorbent (ELISA) kit (Diagnostic Systems Laboratories, Webster, TX). Samples were run in duplicate, and absorbance means were calculated for each animal.
Body Composition
Body fat and nonfat mass were measured by dual-energy X-ray absorptiometry (DEXA) using a PIXImus2 Mouse Densitometer (GE Medical Systems, Madison, WI) with software version 1.46. Field and phantom calibrations were performed as recommended by the manufacturer. The tissue calibration scan was performed with an aluminum/ lucite phantom (bone mineral density ϭ 0.0592 g/cm 2 , percentage fat ϭ 12.5%) prior to each use of the instrument. All DEXA scans excluded the head to include all other body parts in the imaging field. . After a 1-wk acclimation period, animals were anesthetized with ketamine/zylazine (0.1 ml/30 g) to obtain body weight, length (naso-anal), and initial body composition using DEXA. To facilitate measures of energy intake, mice were individually housed in cages with no bedding. Preweighed chow pellets were provided to mice ad libitum, and uningested pellets were collected and weighed every 2-3 days for a period of 7-10 days. Mean energy intake per day was calculated by genotype. After the last measurement of energy intake, animals were euthanized and body weight, length, and body composition (by DEXA) were measured. A similar procedure was employed for 10 F 2 male littermates of each genotype,
Food Intake
md , ϩ/ϩ, and md/md, but the period of food intake measurement was increased to 2 wk, and animals were anesthetized for body composition at the beginning of study with isoflurane.
Calculation of Energy Expenditure
Body composition was obtained by DEXA for each animal at the beginning and end of the food intake experiments to assess the energy content of any change in body mass. The energy contents of lean and fat mass used for this calculation were 1.24 and 9.4 kcal/g, respectively (34) . Fecal loss was not measured. We assumed that all animals lost the same fraction of ingested calories in the feces (29) . We employed the following formulas to calculate energy expenditure for the period of the food intake study: energy output ϭ energy intake Ϫ ⌬energy stored ⌬energy stored ϭ [(⌬lean mass ϫ 1.24 kcal/g) ϩ (⌬fat mass ϫ 9.4 kcal/g)]
Statistical Analyses
Statistical analyses were conducted using GraphPad Prism (version 3.02 for Windows; GraphPad Software, San Diego, CA) and Statis- Table 4 , between-group comparisons were made using a two-tailed unpaired Student's t-test. All data and figures are presented as means Ϯ SE. Differences between means were considered significant at P ␣ Յ0.05.
RESULTS
Effects of Mgrn1 Inactivation on Body Weight and Composition
Body weight. Figure 2 shows mice, and male A y md mice were ϳ2.5% shorter than A y mice. No differences in body length were discerned between ϩ/ϩ controls and md/md.
Effects of Inactivation of Mgrn1 on Food Intake and Energy Expenditure
To assess physiological mechanism(s) for the decreased body fat of A y md vs. A y mice, we compared their food intake and energy expenditure on a standard 10% kcal fat diet. Consistent with previous reports (8, 9) , A y mice (with energy intake of 17.5 Ϯ 0.6 kcal/day) consumed 10 -36% more calories than their lean littermates (Fig. 3A) . Mgrn1 md decreased energy intake in A y md (12.1 Ϯ 0.3 kcal/day) mice, whose energy consumption was not different from ϩ/ϩ (11.5 Ϯ 0.2 kcal/day) animals. In the 1-wk energy balance study, A y animals did not have increased ⌬energy stored (Fig. 3B ) or decreased energy expenditure (Fig. 3C) vs. ϩ/ϩ animals, and energy expenditure of A y md animals was equal to A y and littermate ϩ/ϩ controls (Fig. 3C) . Mc4r-null mice were hyperphagic, ingesting 36% more calories per day than ϩ/ϩ animals (Fig. 3D) . Change in energy stored and calculated energy expenditure were increased in Mc4r-deficient animals vs. ϩ/ϩ animals (Fig. 3, E and F) . No significant differences in energy intake, ⌬energy stored, or energy expenditure were detected between Mc4r Ϫ/Ϫ and Mc4rmd. Data from both crosses indicated that energy intake of md/md animals was not different from ϩ/ϩ.
Effects of Mgrn1 Inactivation on Insulin Sensitivity
Male and female A y md mice, at 8 or 30 -32 wk of age, had reduced plasma concentrations of glucose (reduced ϳ18 -29%) and insulin (reduced ϳ36 -85%) vs. A y ( Ϫ/Ϫ , P Ͻ 0.005 (Table 2) , despite body weight, body composition, and energy intake and expenditure that were not significantly different from Mc4r Ϫ/Ϫ (Table 1 and Fig. 3 ). Homozygosity for Mgrn1 md did not alter the plasma insulin or glucose concentrations of DIO males. In DIO females, fasting plasma glucose was not different between ϩ/ϩ and md/md. However, fasting plasma insulin was significantly reduced (ϳ35%) in md/md vs. ϩ/ϩ DIO females, P Ͻ 0.05 (Table 2) . Mgrn1 md had no effect on the hyperglycemia and hyperinsulinemia of ob/ob mice at 24 wk of age (Table 2) .
To adjust for the contributions of fat mass and plasma glucose to plasma insulin, fat mass and glucose were treated as covariates in an ANCOVA with plasma insulin as the dependent variable (Fig. 4) (Fig. 5) . Homeostatic model assessment (HOMA) was used as an index of insulin sensitivity (30) . Homozygosity for Mgrn1 md increased insulin sensitivity (by HOMA) of A y , Mc4r-null, and DIO animals by 14 -35%, whereas no effect was evident in leptin-deficient (ob/ob) animals (Table 3) . A plot of HOMA values vs. plasma leptin concentration (leptin as surrogate for fat mass) indicated that insulin sensitivity was indistinguishable between ϩ/ϩ and md/md when plasma leptin concentration was less than 1 ng/ml (Fig. 5D ). For plasma leptin concentrations greater than 1 ng/ml, animals homozygous for Mgrn1 md had increased HOMA vs. comparably obese animals that were Mgrn1 ϩ/ϩ . These data suggest that inactivation of Mgrn1 md improves insulin sensitivity by a mechanism independent of the mutation's effects on fat mass.
Effects of Mgrn1 Inactivation on Plasma Leptin Concentrations
Plasma leptin concentrations are increased relative to body fat in A y and Mc4r-null mice (Table 2 ) (8, 31). Homozygosity reflected changes in fat mass. Slopes of adiposity vs. plasma leptin were not significantly different among the genotypes examined (data not shown), indicating that Mgrn1 md had no primary effect on circulating leptin concentration per unit of fat mass. Hence, the effects of Mgrn1 md on insulin sensitivity were not mediated by effects on ambient leptin.
DISCUSSION
Results are summarized in Table 4 . Mgrn1 md could, in theory, reduce body fat by effects on energy intake, energy expenditure, or nutrient partitioning. A y animals display reduced energy expenditure and increased food intake (8, 35) . Hyperphagia is the major factor in the development of A y obesity, since pair feeding of A y to wild-type mice results in A y animals of near-normal body fat content (33) . We found that Mgrn1 md reduced the fat mass of A y mice by suppressing food intake. No effect of Mgrn1 md on energy expenditure of A y was detected. Mgrn1 md had no effect on energy intake or expenditure of 8 wk old Mc4r Ϫ/Ϫ male mice. In an earlier study (18) , md/md animals on the C3H/HeJ background were 20% heavier than ϩ/ϩ controls. We found no difference in weight between md/md and ϩ/ϩ controls when Mgrn1 md was congenic on C57BL/6J. Such previously reported differences are not unexpected given the effects of strain background on monogenic obesities (25) (26) (27) 32) . The effects of Mgrn1 md on body weight and adiposity in A y and Lep ob obesity shown here are not due to strain admixture, since these crosses were between animals segregating for the respective mutant alleles that were fully congenic on C57BL/6J. Additionally, the phenotypes of the wild-type mice were not statistically different among the crosses (data not shown). ) develop vacuolation and abnormal myelination in hippocampus, cerebellar cortex, medulla, midbrain, and thalamus (10), resulting in muscular tremors (16) that may account for some of their increased energy expenditure. Therefore, reduced adiposity and body weight may be due, in part, to increased energy expended in Atrn mg and Atrn mg-3J mice (10) . Like Atrn mg and Atrn mg-3J mice, Mgrn1 nc (but not the Mgrn1 md mice used in this study) show progressive spongiform neurodegeneration that is apparent in the hippocampus at 2 mo and subsequently in other regions, such as the cerebral cortex, thalamus, brain stem, caudate-putamen, and granular layer of the cerebellum (13) . We noted no tremors, ataxic, or movement disorders, and found no gross or microscopic evidence of abnormal myelination or vacuolation in the brain or spinal cords of Mgrn1 md animals at 1 yr of age (21) . Mgrn1 nc is a null allele, whereas the Mgrn1 md mutation reduces Mgrn1 expression by about 95% in the brain (13, 21) . Mgrn1 nc mice are coisogenic on a mixed C3H ϫ 101 stock, whereas Mgrn1 md are congenic on C57BL/6J. CAST/Ei-Atrn mg-6J /Atrn mg-6J animals developed severe tremors (visible at 10 days of age), vacuolization, and sprawling gait and did not survive past 3-4 wk of age (23) . Atrn
mg-6J
, when backcrossed onto the C3H/SnJ strain, showed delayed central nervous system myelination and vacuolization and reduced tremors, and sprawling was no longer evident (24) . Hence, the differences in neurological phenotypes between Mgrn1 nc and Mgrn1 md probably reflect combined effects of mutation severity and background modifier genes.
The their body weights and adiposities were comparable to littermate controls.
Insulin and leptin circulate in plasma at concentrations proportional to body fat mass (1, 6, 24, 36) . A y , Mc4r-null, and ϩ/ϩ DIO mice demonstrated the expected correlations between body fat mass (by DEXA) and plasma insulin concentrations, suggesting that the increased plasma insulin in these animals is primarily a function of the increased fat mass. In contrast, introduction of Mgrn1 md in A y , Mc4r-null, or ϩ/ϩ DIO mice altered the significant correlation between fat mass and circulating insulin concentrations, indicating that hypoactivity of MGRN1 lowers plasma insulin concentrations and increases insulin sensitivity by a mechanism independent of effects on fat mass. Intracerebroventricular administration of the MC3R/MC4R agonist, MTII, increases Glut4 mRNA expression in skeletal muscle and enhances insulin action in mice independently of its effects on food intake or body weight (14 md does not act via the MC4R-signaling pathway to regulate insulin homeostasis. The effects on insulin sensitivity could be mediated through MC3R. The preferential effects of MC3R on fuel efficiency and caloric partitioning and hyperinsulinemia of male Mc3r-null mice are consistent with MC3R-mediated effects on insulin homeostasis (3, 4, 7) . MC3R allelic variants have been weakly associated with insulin sensitivity in human subjects (12) .
Atrn mg appears to rescue the A y obesity phenotype by increasing physical activity. Homozygosity for Atrn mg also suppresses the hyperinsulinemia of A y , but it is not clear that this effect is not fully accounted for by reduced body fat (8) . Mahogany and mahoganoid are loss-of-function mutations that act epistatically to A y to suppress both the yellow coat color and obesity caused by ectopic overexpression of ASP (18); the expression patterns of Atrn and Mgrn1 mRNA are similar (11, 13, 17) . These findings suggest that ATRN and MGRN1 are required for ASP effects in both the skin and the brain, and that they function in the same genetic pathway. Atrn transgenes are unable to rescue the brain vacuolization phenotype of Mgrn1 nc , and Mgrn1 have no effects on Atrn expression levels (13), placing MGRN1 functionally downstream of ATRN. MGRN1 is an intracellular C3HC4 RING finger domain protein that has E3 ubiquitin ligase activity (13, 21) . It is probable that MGRN1 affects energy and insulin homeostasis via the agouti-signaling pathway by 1) increasing expression, activity, or localization of the inverse agonist/antagonist to MC3R/MC4R receptors; 2) influencing the physical proximity or increasing binding of a possible coreceptor, such as ATRN, to ASP; or 3) targeting ATRN-associated proteins for ubiquitination (Fig. 1) . Identifying the molecular targets of MGRN1 could identify new 
